In vivo CAR T cell generation to treat cancer and autoimmune disease | ⁦Science Magazine⁩ science.org/doi/10.1126/sc…

Huge shoutout and thank you to our dynamic Podocyte Social Media Team - Gabriela Amador Reyes and António Da Silva Inácio. They kept our community buzzing with constant updates and important insights! #PodocyteConference

Meet & Greet was a success! Thanks to all participants! 🎉 #ERA25 ERA - European Renal Association

Hamburg News: Study by the Krebs/ Panzer/ Asada team reveals that IFN-I induces cytotoxic ISG-T cells in lupus and AAV glomerulonephritis - uncovering a critical IFN-I–T cell axis in autoimmune kidney injury. HCKH_Hamburg UKE Hamburg CKLab nature.com/articles/s4146…

Membranous nephropathy (MN) antigens from a single center in Portugal. Starting point=negative serum anti-PLA2R titer cases. We detected MN antigens: 3 PLA2R, 2 NELL1, & 1 each EXT1/EXT2, HTRA1, THSD7A. Antigens correlated with underlying disease. 1/2 kireports.org/article/S2468-…

Check out our work on Membranous Nephropathy antigens using LMD/MS 👇 Interesting results! 🔎 Such a great honor to work with Sanjeev Sethi and the Mayo Clinic Nephrology and Mayo Clinic Labs team! fernando fervenza Mayo Clinic

IL-7Ra signalling in AAV links to relapse/resistance Our recent paper 🔹defined activated & exhausted T cells in experimental AAV kidneys 🔹neutralised IL-7Ra - a non-depleting mAb - to limit ANCA-associated GN Similar mAbs are in Phase 2 clinical trials academic.oup.com/ndt/article-ab…

I love a good title. Here is one turkjnephrol.org/en/pauci-immun…

Sex-specific clinical presentations and outcomes in ANCA vasculitis presenting with severe kidney disease doi.org/10.1093/ndt/gf…

Male patients with AAV-GN and eGFR <15 start dialysis earlier than female. However, progression to ESKD at 12 months is not different. This is associated with chronic changes in kidney histopathology but not with sex Maria Jose Soler fernando fervenza Sanjeev Sethi Mayo Clinic Nephrology✨

Long-term Outcome of #Adult Patients With #Membranous Nephropathy Treated With #Rituximab #VisualAbstract by Dr Priti MD,FASN🇮🇳 (प्रिति) kireports.org/article/S2468-…

Time is critical in AAV: dampening kidney inflammation prevents damage Why not target effector T cells - leave other T cells alone? Our paper in @NDTSocial defines IL-7Ra as a target doi.org/10.1093/ndt/gf… Anti-IL-7Ra Abs are in Phase 2 trials - alopecia Q32 Bio Inc. ?an AAV therapy

Antigens in membranous nephropathy: discovery and clinical implications nature.com/articles/s4158…

Membranous nephropathy has undergone a paradigm shift due to the discovery of unique MN antigens. MN has gone from idiopathic to ➡️ primary vs. secondary ➡️ where an antigen can be detected in ~80% of MN. This is a comprehensive review of each antigen. nature.com/articles/s4158…

FAT1 is the target antigen in membranous nephropathy associated with- 1. Stem cell transplant (HSCT) 2. Antibody mediated rejection (ABMR) in allograft. In this paper we show a temporal ⬆️of FAT1 in MN with ABMR using protocol & for cause biopsies. kireports.org/article/S2468-… 1/2

Now online in NDT Perlecan is a novel target of autoantibodies in anti-glomerular basement membrane disease 🧐Triple-positive pts (anti-type IV collagen, -laminin 521, and -perlecan) = highest prevalence of lung hemorrhage and ESKD ▶️academic.oup.com/ndt/article-ab…

"All that glitters is not gold." We finally see ALCHEMIST & ACHIEVE published, which - together with BARACK-D - refute DOHAS findings that MRA improve CV outcome in dialysis pat. Kudos, Patrick Rossignol and Michael Walsh, for questioning DOHAS that looked too good to be true.

Extracellular DNA is known to induce inflammation, but does it drive kidney damage in autoimmune vasculitis? Dr. Kim O’Sullivan & team Monash University report on targeting ecDNA with DNAase I in models of MPO-ANCA vasculitis. See full report: insight.jci.org/articles/view/…

Baffling: PGNMID, monoclonal no more I got this consult case as immune complex-MPGN LM- MPGN pattern IF- IgG, C3, C1q, kappa & lambda 3+ Did IgG subtypes-IgG3 3+, all others negative EM- mottled deposits Dx- Proliferative GN, IgG3, but ? with monoclonal IgG deposits (PGNMID)

Complement Inhibition Enables Anti-VEGF Receptor Therapy in Renal-Limited TMA. More options to keep patients on life-saving therapy. Check it out.👇🏽⁦ISN Education⁩ ⁦Elena-Bianca Barbir, MD⁩ ⁦KIReports⁩ Abdullah Jalal⁩ ⁦Mayo Clinic Nephrology⁩ kireports.org/article/S2468-…